Prevention of mother-to-child transmission of hepatitis B virus : guidelines on antiviral prophylaxis in pregnancy
WHO estimates that in 2015, 257 million people were living with chronic hepatitis B virus (HBV) infection worldwide, and that 900 000 had died from HBV infection, mostly as a result of cirrhosis or hepatocellular carcinoma. Most HBV-associated deaths among adults are secondary to infections acquired at birth or in the first five years of life. In May 2016, the World Health Assembly endorsed the Global health sector strategy on viral hepatitis, which calls for the elimination of viral hepatitis as a public health threat by 2030 (defined as a 90% reduction in incidence of new infections and a 65% reduction in mortality). Elimination of HBV infection as a public health threat requires a reduction in the prevalence of hepatitis B surface antigen (HBsAg) to below 0.1% in children 5 years of age. This can be achieved through universal immunization of newborns against hepatitis B and other interventions to prevent mother-to-child transmission of HBV. These guidelines provide evidence-based guidance on the use of peripartum antiviral prophylaxis in HBsAg-positive pregnant women for the prevention of mother-to-child transmission of HBV..
Medienart: |
E-Book |
---|
Erscheinungsjahr: |
July 2020 |
---|---|
Erschienen: |
Geneva: World Health Organization ; July 2020 |
Sprache: |
Englisch |
---|
Links: |
www.ncbi.nlm.nih.gov [teilw. kostenfrei] |
---|
ISBN: |
---|
Themen: |
Antiviral Agents |
---|
Anmerkungen: |
Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed January 13, 2021) |
---|
Umfang: |
1 online resource (1 PDF file (xiv, 41 pages)) ; illustrations |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
177318461X |
---|
LEADER | 01000cam a22002652 4500 | ||
---|---|---|---|
001 | 177318461X | ||
003 | DE-627 | ||
005 | 20230428011921.0 | ||
007 | cr uuu---uuuuu | ||
008 | 211011s2020 xx |||||o 00| ||eng c | ||
020 | |a 9789240002708 |c electronic version |9 978-92-4-000270-8 | ||
035 | |a (DE-627)177318461X | ||
035 | |a (DE-599)KEP068718306 | ||
035 | |a (NCBI)1771642 | ||
035 | |a (EBP)068718306 | ||
040 | |a DE-627 |b ger |c DE-627 |e rda | ||
041 | |a eng | ||
245 | 1 | 0 | |a Prevention of mother-to-child transmission of hepatitis B virus |b guidelines on antiviral prophylaxis in pregnancy |
264 | 1 | |a Geneva |b World Health Organization |c July 2020 | |
300 | |a 1 online resource (1 PDF file (xiv, 41 pages)) |b illustrations | ||
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed January 13, 2021) | ||
520 | |a WHO estimates that in 2015, 257 million people were living with chronic hepatitis B virus (HBV) infection worldwide, and that 900 000 had died from HBV infection, mostly as a result of cirrhosis or hepatocellular carcinoma. Most HBV-associated deaths among adults are secondary to infections acquired at birth or in the first five years of life. In May 2016, the World Health Assembly endorsed the Global health sector strategy on viral hepatitis, which calls for the elimination of viral hepatitis as a public health threat by 2030 (defined as a 90% reduction in incidence of new infections and a 65% reduction in mortality). Elimination of HBV infection as a public health threat requires a reduction in the prevalence of hepatitis B surface antigen (HBsAg) to below 0.1% in children 5 years of age. This can be achieved through universal immunization of newborns against hepatitis B and other interventions to prevent mother-to-child transmission of HBV. These guidelines provide evidence-based guidance on the use of peripartum antiviral prophylaxis in HBsAg-positive pregnant women for the prevention of mother-to-child transmission of HBV. | ||
650 | 2 | |a Hepatitis B |x drug therapy |0 https://id.nlm.nih.gov/mesh/D006509Q000188 | |
650 | 2 | |a Antiviral Agents |x therapeutic use |0 https://id.nlm.nih.gov/mesh/D000998Q000627 | |
650 | 2 | |a Pregnancy Complications, Infectious |x drug therapy |0 https://id.nlm.nih.gov/mesh/D011251Q000188 | |
650 | 2 | |a Infectious Disease Transmission, Vertical |x prevention & control |0 https://id.nlm.nih.gov/mesh/D018445Q000517 | |
650 | 2 | |a Hepatitis B virus |0 https://id.nlm.nih.gov/mesh/D006515 | |
655 | 2 | |a Practice Guideline |0 https://id.nlm.nih.gov/mesh/D017065 | |
710 | 2 | |a World Health Organization. |b Global Hepatitis Programme, |e MitwirkendeR |4 ctb | |
856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/books/NBK561127/ |m X:NCBI |x Verlag |z teilw. kostenfrei |
912 | |a ZDB-193-NCB | ||
912 | |a GBV_ILN_22 | ||
912 | |a ISIL_DE-18 | ||
912 | |a SYSFLAG_1 | ||
912 | |a GBV_KXP | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_22_i06404 | ||
912 | |a GBV_ILN_40 | ||
912 | |a ISIL_DE-7 | ||
912 | |a GBV_ILN_74 | ||
912 | |a ISIL_DE-354 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a ISIL_DE-25 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a ISIL_DE-180 | ||
912 | |a GBV_ILN_2010 | ||
912 | |a ISIL_DE-15 | ||
951 | |a BO | ||
980 | |2 22 |1 01 |x 0018 |b 3994081688 |h h64 NCBI |y zi06404 |z 21-10-21 | ||
980 | |2 40 |1 01 |x 0007 |b 3994007933 |h OLR-NCB-BOOKSHELF |y xsn |z 21-10-21 | ||
980 | |2 74 |1 01 |x 0354 |b 3999784210 |c 09 |f E-Bibl |d EM 0000 |e --%%-- |j --%%-- |y ze |z 08-11-21 | ||
980 | |2 2003 |1 01 |x DE-25 |b 3995674089 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 25-10-21 | ||
980 | |2 2009 |1 01 |x DE-180 |b 3987674199 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 11-10-21 | ||
980 | |2 2010 |1 01 |x DE-15 |b 3987760400 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 11-10-21 | ||
981 | |2 22 |1 01 |x 0018 |r https://www.ncbi.nlm.nih.gov/books/NBK561127/ | ||
981 | |2 40 |1 01 |x 0007 |y Volltext, Open Access |r https://www.ncbi.nlm.nih.gov/books/NBK561127/ | ||
981 | |2 74 |1 01 |x 0354 |r https://www.ncbi.nlm.nih.gov/books/NBK561127/ | ||
981 | |2 2003 |1 01 |x DE-25 |r https://www.ncbi.nlm.nih.gov/books/NBK561127/ | ||
981 | |2 2010 |1 01 |x DE-15 |y Online-Zugriff |r https://www.ncbi.nlm.nih.gov/books/NBK561127/ | ||
985 | |2 22 |1 01 |x 0018 |a h64 ebook | ||
985 | |2 74 |1 01 |x 0354 |a EM 0000 | ||
995 | |2 22 |1 01 |x 0018 |a h64 NCBI | ||
995 | |2 22 |1 01 |x 0018 |a h64 freie Ressource | ||
995 | |2 40 |1 01 |x 0007 |a OLR-NCB-BOOKSHELF |